EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data

Yun Fan1,2
Xiaoling Xu1
Conghua Xie3,4

1Zhongnan Hospital of Wuhan University, Department of Radiation Oncology, Wuhan, People's Republic of China; 2Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China; 3Department of Radiation Oncology, Wuhan, People's Republic of China; 4Zhongnan Hospital of Wuhan University, Department of Radiation Oncology, Wuhan, People's Republic of China

Introduction: Brain metastases are one of the leading causes of death from non-small-cell lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) to treat brain metastases remains controversial. Thus, we performed a pooled analysis of published data to evaluate the efficacy of EGFR-TKIs in NSCLC patients with brain metastases, particularly for tumors with activating EGFR mutations.

Methods: Several data sources were searched, including PubMed, Web of Science, and ASCO Annual Meetings databases. The end points were intracranial overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events. The pooled ORR, DCR, PFS, and OS with 95% confidence intervals (CIs) were calculated employing fixed- or random-effect models, depending on the heterogeneity of the included studies.

Results: Sixteen published studies were included in this analysis, with a total of 464 enrolled patients. The EGFR mutational status was unknown for 362 (unselected group), and 102 had activating EGFR mutations. The pooled intracranial ORR and DCR were 51.8% (95% CI: 45.8%–57.8%) and 75.7% (95% CI: 70.3%–80.5%), respectively. A higher ORR was observed in the EGFR mutation group than in the unselected group (85.0% vs 45.1%); a similar trend was observed for the DCR (94.6% vs 71.3%). The pooled median PFS and OS were 7.4 months (95% CI, 4.9–9.9) and 11.9 months (95% CI, 7.7–16.2), respectively, with longer PFS (12.3 months vs 5.9 months) and OS (16.2 months vs 10.3 months) in the EGFR mutation group than in the unselected group.

Conclusion: This pooled analysis strongly suggests that EGFR-TKIs are an effective treatment for NSCLC patients with brain metastases, particularly in those patients harboring EGFR mutations. Larger prospective randomized clinical trials are warranted to confirm our conclusion and identify the most appropriate treatment model.

Keywords: NSCLC, brain metastases, epidermal growth factor receptor, tyrosine kinase inhibitors

Introduction

Brain metastases are a frequent complication in patients with non-small-cell lung cancer (NSCLC), and approximately 25%–40% of NSCLC patients develop brain metastases during their disease course.1,2 Traditionally, whole-brain radiation therapy (WBRT) has been the standard treatment for brain metastases with multiple intracranial lesions; in some cases, surgical resection, stereotactic radiosurgery, or some combination of the three can be used.3–6 However, the therapeutic effects are limited and the prognosis remains poor. Median survival ranges from 2.4 months to 4.8 months for patients with...
brain metastases who receive WBRT alone. Because it is assumed that most chemotherapeutic agents cannot cross the blood–brain barrier, the efficacy of these drugs in controlling NSCLC-related brain metastases remains controversial.

Erlotinib and gefitinib, small-molecule tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR), have been shown to improve survival in NSCLC when used as a second-line therapy compared with placebo either for an entire unselected group of NSCLC patients or in certain subgroups, such as never-smokers or patients of Asian origin. Subsequently, activating EGFR mutations were determined to be predictive parameters of the response to EGFR-TKI therapy in NSCLC. EGFR-TKIs are now recognized as a standard first-line therapy replacing conventional cytotoxic chemotherapy for patients with activating EGFR mutations in response to randomized studies that demonstrated significantly higher tumor overall response rates (ORR) and longer progression-free survival (PFS). In contrast, for previously treated patients with wild-type EGFR, compared with first-generation EGFR-TKIs, conventional chemotherapy was associated with improvement in PFS.

Evidence suggests that EGFR-TKIs can penetrate the blood–brain barrier. Several case reports and studies with a small series of patients have indicated successful treatment of brain metastases with TKIs. However, the results were not consistent with the cerebral ORR of 10%–86% and PFS of 3–10 months. Most of these studies included small sample sizes, retrospective analyses, and case reports with inadequate power to exclude clinically relevant differences in efficacy. Thus, we performed the present pooled analysis to evaluate the efficacy of EGFR-TKIs in NSCLC patients with brain metastases, particularly in NSCLC patients harboring activating EGFR mutations.

Methods

Literature search strategy

The selection of publications for inclusion was performed independently by two authors (Yun Fan and Xiaoling Xu), with the last search performed on December 25, 2013. A computerized search was performed using the PubMed (from 1966 to the present), Web of Science (from 1945 to the present), online proceedings of the ASCO Annual Meetings (from 2007 to the present), EBSCO (from 1975 to the present), MEDLINE (from 1975 to the present), and Springer Link (from 1997 to the present) databases using the following search keywords: “lung cancer”, “non-small-cell lung cancer”, “brain metastases”, “EGFR-TKI”, “erlotinib”, and “gefitinib”. Manual searches were performed by reviewing the reference lists of the retrieved studies and review articles to identify additional potentially eligible studies.

Study eligibility

Study selection was based on an initial screening of the identified abstracts or titles and a second screening of the full-text articles. Studies were considered eligible if they met the following criteria: 1) prospective cohorts, retrospective designs, or clinical trials were all included because of the small number of relevant articles; 2) patients with brain metastases from NSCLC were treated with erlotinib or gefitinib; and clinical trials were all included because of the small number of relevant articles; 2) patients with brain metastases from NSCLC were treated with erlotinib or gefitinib; 3) the events of intracranial complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD), ORR, and disease control rate (DCR) were reported; 4) PFS and overall survival (OS) with corresponding 95% confidence intervals (CIs) were reported; 5) the number of study cases was greater than five; and 6) the publication was written in English. Research protocol articles, case reports, letters to the editor, reviews, articles based on guidelines, and articles published in books were not included.

Data extraction and quality assessment

In all identified reports, NSCLC patients with brain metastases were treated with gefitinib or erlotinib. The treatment response was determined by the Response Evaluation Criteria in Solid Tumors (RECIST), and toxicities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0 or 3.0. The following information was extracted from each publication: first author, year of publication, number of patients analyzed, median age or mean age of the population, performance status, type of study, EGFR mutation, former treatments before target therapy, duration of follow-up, adverse reaction, and the events of CR, PR, SD or PD, and PFS or OS, with corresponding 95% CIs. To extract the data, two of the authors (Yun Fan and Xiaoling Xu) independently extracted the information from each eligible publication. Any disagreement was settled by a third investigator (Conghua Xie). No authors of the original publications were contacted for verification or clarification of their data.

Statistical analysis

ORR was defined as CR plus PR, whereas DCR was defined as the best tumor response of CR plus PR plus SD. The rates of both responses to EGFR-TKI target therapy for brain metastases in NSCLC patients were calculated as the event rate along with the 95% CI. Toxicity was summarized...
using descriptive statistics. The fixed-effects model (Mantel–Haenszel method) was used for cases with no significant heterogeneity. Otherwise, the random-effects model (DerSimonian and Laird method) was used. The homogeneity of the studies was tested by the $Q$ statistic (significance level at $P>0.10$) and the $I^2$ statistic ($I^2=0\%–50\%$ for no or moderate heterogeneity; $I^2>50\%$, significant heterogeneity), which are quantitative measures of inconsistency across studies.29

Funnel plots were used to evaluate possible publication bias regarding each study outcome. We conducted subgroup analyses stratified by EGFR mutation status, study type, concurrent WBRT, type of EGFR-TKI used, and histology type to assess the impact of these variables on outcomes. We also conducted a sensitivity analysis to investigate the influence of a single study on the overall risk estimate by omitting one study in turn. All tests were two-sided, and a $P$-value less than 0.05 was considered significant. All statistical analyses, including the combined ORR, DCR, and median pooled PFS and OS, were calculated using Meta-Analyst software30 (Version Beta 3.13; Tufts Evidence-based Practice Center, Boston, MA, USA) using the one-arm binary or continuous analysis function.

**Results**

**Literature search**

A flow chart showing the studies involved is presented in Figure 1. Briefly, we identified 151 records by searching the specified databases, and 30 records were identified through other sources, such as the references of published articles and conference articles. After removing duplicate records, 120 records remained. Further screening revealed that

---

**Figure 1** Selection of publications included in the pooled analysis.

**Abbreviations:** EGFR-TKIs, small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; WBRT, whole-brain radiation therapy.
43 potential studies were full-text articles. After eliminating articles that did not satisfy the selection criteria, did not permit the extraction of sufficient data, or were not relevant, 16 studies23–27,31–41 published between 2003 and 2013 were finally selected that met the qualitative and quantitative requirements of the systematic analysis.

Characteristics of the studies

Of the 16 included articles, six were Phase II single-arm trials, one was a Phase I single-arm trial, five were prospective in design, and four were retrospective analyses. Four hundred sixty-four patients were enrolled in this pooled analysis. Among them, approximately half of the patients were from East Asia, including China, Japan, and Korea, while the others were from Western countries and the US. The median age of the patients ranged from 54 years to 65.5 years. The patients of most studies had a performance status of 0–3, and the median length of follow-up ranged from 2.6 months to 28.5 months. In addition, the patients in most of the unselected studies had received prior chemotherapy or radiotherapy.

All patients were treated with oral gefitinib or erlotinib and were followed until disease progression, death, or intolerable side effects. Of the 464 enrolled patients, the EGFR mutational status was unknown for 362 (unselected group), and 102 harbored activating EGFR mutations. The ORR for EGFR-TKI treatment was available for 428 patients: 358 patients with brain metastases from NSCLC were treated with EGFR-TKI only, and the other 70 patients were treated with EGFR-TKIs plus concurrent WBRT. PFS and OS were available in eight and ten studies, respectively. Two reports2,11 only included patients with EGFR mutations, and three other studies9,15,21 provided data for extracting ORR, DCR, PFS, and OS in patients with and without EGFR mutations. The remaining studies did not provide patients with the EGFR mutation status. The details of the patient demographics and study designs are included in Table 1.

Main analysis

Based on the search strategy, 16 eligible studies were identified and included in the pooled analysis for ORR and DCR. Due to the modest significant heterogeneity of ORR (Q statistic, 0.991; F, 0.468) and DCR (Q statistic, 0.986; F, 0.447), the fixed-effects model was used to analyze the data. The pooled ORR was 51.8% (95% CI: 45.8%–57.8%, Figure 2A), and the pooled DCR was 75.7% (95% CI: 70.3%–80.5%, Figure 2B). By contrast, significant heterogeneity (I²>50%) was observed in both PFS (7.4; 95% CI: 4.9–9.9; Figure 2C) and OS (11.9; 95% CI: 7.7–16.2; Figure 2D), and thus the random-effects model was used. The weighted overall median PFS and survival time were 7.4 months (95% CI: 7.7–16.2; Figure 2C) and 11.9 months (95% CI: 4.9–9.9; Figure 2D), respectively.

Table 1 Characteristics of the studies

<table>
<thead>
<tr>
<th>Authors</th>
<th>Type of study</th>
<th>EGFR mutation (+)</th>
<th>Whether concurrent WBRT</th>
<th>Number of patients</th>
<th>The type of EGFR-TKI</th>
<th>ORR, %</th>
<th>DCR, %</th>
<th>PFS, months</th>
<th>OS, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bai and Han26</td>
<td>Retrospective</td>
<td>Part of patients</td>
<td>No</td>
<td>40</td>
<td>Erlotinib</td>
<td>10.00</td>
<td>62.50</td>
<td>3</td>
<td>9.2</td>
</tr>
<tr>
<td>Ceresoli et al24</td>
<td>Prospective</td>
<td>Unselected</td>
<td>No</td>
<td>41</td>
<td>Gefitinib</td>
<td>9.80</td>
<td>26.80</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Chiu et al14</td>
<td>Prospective</td>
<td>Unselected</td>
<td>No</td>
<td>21</td>
<td>Gefitinib</td>
<td>50.00</td>
<td>90.48</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hotta et al33</td>
<td>Retrospective</td>
<td>Unselected</td>
<td>No</td>
<td>14</td>
<td>Gefitinib</td>
<td>42.86</td>
<td>100.00</td>
<td>8.8</td>
<td>9.1</td>
</tr>
<tr>
<td>Iuchi et al17</td>
<td>Phase II</td>
<td>All the patients</td>
<td>No</td>
<td>41</td>
<td>Gefitinib</td>
<td>87.80</td>
<td>97.56</td>
<td>14.5</td>
<td>21.9</td>
</tr>
<tr>
<td>Kim et al17</td>
<td>Prospective</td>
<td>Unselected</td>
<td>No</td>
<td>23</td>
<td>Gefitinib or erlotinib</td>
<td>73.90</td>
<td>82.60</td>
<td>7.1</td>
<td>18.8</td>
</tr>
<tr>
<td>Lind et al10</td>
<td>Phase I</td>
<td>Unselected</td>
<td>Yes</td>
<td>7</td>
<td>Erlotinib</td>
<td>71.43</td>
<td>100.00</td>
<td>NA</td>
<td>4.7</td>
</tr>
<tr>
<td>Ma et al37</td>
<td>Phase II</td>
<td>Unselected</td>
<td>Yes</td>
<td>21</td>
<td>Erlotinib</td>
<td>80.95</td>
<td>95.24</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>Namba et al32</td>
<td>Prospective</td>
<td>Unselected</td>
<td>No</td>
<td>11</td>
<td>Gefitinib</td>
<td>81.82</td>
<td>100.00</td>
<td>2.4</td>
<td>12</td>
</tr>
<tr>
<td>Olmez et al41</td>
<td>Retrospective</td>
<td>Unselected</td>
<td>Yes</td>
<td>8</td>
<td>Erlotinib</td>
<td>33.33</td>
<td>100.00</td>
<td>NA</td>
<td>1.4</td>
</tr>
<tr>
<td>Park et al34</td>
<td>Phase II</td>
<td>All the patients</td>
<td>Yes</td>
<td>27</td>
<td>Gefitinib or erlotinib</td>
<td>85.19</td>
<td>96.30</td>
<td>6.6</td>
<td>15.9</td>
</tr>
<tr>
<td>Porta et al38</td>
<td>Retrospective</td>
<td>Part of patients</td>
<td>No</td>
<td>53</td>
<td>Erlotinib</td>
<td>26.42</td>
<td>84.91</td>
<td>2.9</td>
<td>4.3</td>
</tr>
<tr>
<td>Rosell et al32</td>
<td>Prospective</td>
<td>All the patients</td>
<td>Yes</td>
<td>30</td>
<td>Erlotinib</td>
<td>NR</td>
<td>NR</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>Welsh et al35</td>
<td>Phase II</td>
<td>All the patients</td>
<td>Yes</td>
<td>40</td>
<td>Erlotinib</td>
<td>91.67</td>
<td>94.44</td>
<td>8</td>
<td>11.8</td>
</tr>
<tr>
<td>Wu et al37</td>
<td>Phase II</td>
<td>Unselected</td>
<td>No</td>
<td>40</td>
<td>Gefitinib</td>
<td>37.50</td>
<td>82.50</td>
<td>9</td>
<td>15</td>
</tr>
<tr>
<td>Wu et al37</td>
<td>Phase II</td>
<td>Part of patients</td>
<td>No</td>
<td>47</td>
<td>Erlotinib</td>
<td>59.57</td>
<td>76.60</td>
<td>10.1</td>
<td>18.9</td>
</tr>
</tbody>
</table>

Abbreviations: DCR, disease control rate; EGFR, epidermal growth factor receptor; NA, not available; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiation therapy.
Side effects were generally mild and consisted mainly of diarrhea, skin toxicity, and liver dysfunction, with respective incidences of 0%–60.0%, 7.4%–100%, and 0%–18.2% (Table 1).

Subgroup and sensitivity analyses
The high degree of heterogeneity between the studies warranted explanation. Therefore, subgroup analysis was performed. Table 2 shows the results of subgroup analyses stratified by EGFR mutation status, study type, concurrent WBRT, the type of EGFR-TKI used, and histology type.

In the subgroup analysis, among patients with brain metastases from NSCLC who harbored EGFR mutations, fine homogeneity was observed in the combined data for the pooled ORR (Q statistic, 0.514; F, 0.000), DCR (Q statistic, 0.700; F, 0.000), PFS (F, 0.000), and OS (F, 0.200). The ORR (Figure 3A) was higher in the EGFR mutation group (85.0%, 95% CI: 76.5%–90.7%) than in the unselected
group (unknown EGFR mutational status) (45.1%, 95% CI: 37.6%–52.8%), and a similar trend was observed for the DCR (Figure 3B) (94.6%, 95% CI: 87.1%–97.9% vs 71.3%, 95% CI: 65.0%–76.8%, respectively). The pooled PFS (Figure 3C) was longer in the EGFR mutation group than in the unselected group: 12.3 months (95% CI: 10.4–14.3) versus 5.9 months (95% CI: 3.5–8.4), with no evidence of heterogeneity in the EGFR mutation group ($I^2=0.525$, $P=0.000$). Similarly, the pooled OS (Figure 3D) was longer in the EGFR mutation group than in the unselected group: 16.2 months versus 10.3 months, respectively.

In addition, no significant heterogeneity was observed in the Phase II studies ($P<0.50$). The Phase II studies reported higher ORR (Figure 2A) and DCR (Figure 2B) rates and more favorable survival (Table 2). EGFR-TKIs plus concurrent WBRT yielded a higher ORR (66.2% vs 47.1%) and DCR (94.4% vs 73.1%) than treatment with EGFR-TKIs alone. Moreover, patients with brain metastases from NSCLC treated with gefitinib had improved survival compared with those treated with erlotinib (14.1 months vs 9.7 months).

### Sensitivity analyses and publication bias

The sensitivity analyses demonstrated that no individual study affected the ORR, DCR, PFS, and OS, because omission of any single study did not significantly affect these parameters. No evidence of publication bias was found with regard to ORR, DCR, PFS, and OS in relation to EGFR-TKI treatment for patients with brain metastases from NSCLC, as suggested by the funnel plot. In addition, no significant publication bias was identified in the EGFR mutation group (Figure 4) and Phase II studies.

### Discussion

The present pooled analysis included 464 patients from 16 trials; approximately half of the patients were from East Asia, while the others were from Western countries and the US. The primary objective was to evaluate the value of EGFR-TKI therapy in patients with brain metastases from NSCLC. We believe that our pooled analysis strengthens the individual observations of each of these small prospective and retrospective studies. The results confirmed that in this population of patients, EGFR-TKIs yield significant beneficial effects, with a pooled intracranial ORR of 51.8%, DCR of 75.7%, median PFS of 7.4 months, and OS of 11.9 months. These results were associated with a longer OS than with WBRT alone.7,8 At least two reasons for the therapeutic efficacy of EGFR-TKIs in NSCLC patients with brain metastases can be proposed. First, EGFR-TKIs might penetrate the brain–blood barrier to reach the intracranial lesion; the documented data revealed penetration rates of 1.13%±0.36% and 2.77%±0.45% for gefitinib and erlotinib, respectively.21,22,42 Second, a considerable proportion of patients with brain metastases also have extracranial lesions and require systemic medication. Thus, EGFR-TKIs represent an effective therapy in advanced NSCLC.

The EGFR mutation status seems to be the strongest correlate of the response to EGFR-TKIs.11–13 However, EGFR mutations in the human population are apparently heterogeneous. For instance, Paez et al12 reported mutation differences

### Table 2 Results from subgroup analysis

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Pooled ORR and 95% CI, model</th>
<th>Pooled DCR and 95% CI, model</th>
<th>Pooled PFS (months) and 95% CI, model</th>
<th>Pooled OS (months) and 95% CI, model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>0.604 (0.493–0.706), fixed</td>
<td>0.728 (0.662–0.784), fixed</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Unselected</td>
<td>0.484 (0.415–0.555), fixed</td>
<td>0.728 (0.662–0.784), fixed</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Study design</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retrospective study</td>
<td>0.251 (0.176–0.346), fixed</td>
<td>0.756 (0.658–0.833), fixed</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Prospective study</td>
<td>0.468 (0.334–0.607), fixed</td>
<td>0.417 (0.348–0.674), fixed</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Phase II study</td>
<td>0.677 (0.600–0.745), fixed</td>
<td>0.856 (0.792–0.903), fixed</td>
<td>10.573 (9.192–11.953), fixed</td>
<td>15.685 (13.303–17.868), fixed</td>
</tr>
<tr>
<td>EGFR mutation status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mutation</td>
<td>0.850 (0.765–0.907), fixed</td>
<td>0.946 (0.871–0.979), fixed</td>
<td>12.334 (10.411–14.257), fixed</td>
<td>16.169 (12.261–20.076), fixed</td>
</tr>
<tr>
<td>Unselected</td>
<td>0.451 (0.376–0.528), fixed</td>
<td>0.713 (0.650–0.768), fixed</td>
<td>5.937 (3.518–8.356), random</td>
<td>10.318 (5.013–15.623), random</td>
</tr>
<tr>
<td>Whether concurrent WBRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.662 (0.791–0.880), fixed</td>
<td>0.944 (0.860–0.979), fixed</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>No</td>
<td>0.471 (0.408–0.535), fixed</td>
<td>0.731 (0.671–0.784), fixed</td>
<td>6.965 (4.450–9.480), random</td>
<td>13.565 (8.104–19.025), random</td>
</tr>
<tr>
<td>The type of EGFR–TKI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gefitinib</td>
<td>0.518 (0.426–0.609), fixed</td>
<td>0.687 (0.582–0.776), fixed</td>
<td>8.903 (3.909–13.897), random</td>
<td>14.131 (11.878–16.384), fixed</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>0.443 (0.358–0.531), fixed</td>
<td>0.778 (0.706–0.836), fixed</td>
<td>5.937 (3.270–8.607), random</td>
<td>9.714 (4.168–15.259), random</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; DCR, disease control rate; EGFR, epidermal growth factor receptor; NA, not available; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; WBRT, whole-brain radiation therapy.
according to sex (20% vs 9% for females and males, respectively), tumor histology (21% vs 2% for adenocarcinoma and other types, respectively), and ethnicity (26% vs 2% for Asian and North American populations, respectively). Recently, Shi et al tested 1,482 NSCLC patients with adenocarcinoma from seven Asian regions and found an overall rate of \( EGFR \) mutations of 5.14%. However, the rate was 15.0% in similar patients in the US. Thus, the efficacy of EGFR-TKI treatment may depend on the treated population. Therefore, to exclude possible confounding factors, we conducted subgroup analysis by dividing the patients into an \( EGFR \) mutation group and an unselected group (unknown \( EGFR \) mutational status). Our data demonstrated that, compared with the unselected group, therapeutic benefits are observed in patients with \( EGFR \) mutations with an ORR of 85.0% versus 45.1% and a DCR of 94.6% versus 71.3% for the \( EGFR \) mutation and unselected groups, respectively. \( EGFR \) mutations also showed therapeutic advantage over unselected groups in terms of median progression-free survival (12.3 months vs 5.9 months) and median survival time (16.2 months vs 10.3 months), indicating that EGFR-TKIs may be suitable for the treatment of brain metastases in patients with \( EGFR \) mutations.

Figure 3 Results of subgroup analyses.

Notes: (A) Pooled analysis for response rate in the epidermal growth factor receptor (EGFR) mutation group. (B) Pooled analysis for disease control rate in the EGFR mutation group. (C) Pooled analysis for progression-free survival in the EGFR mutation group. (D) Pooled analysis for overall survival in the EGFR mutation group.
mutations. Currently, EGFR-TKIs are approved for use as a first-line therapy for patients with EGFR-mutated lung cancer, and it seems reasonable to consider EGFR-TKIs as a first-line treatment for EGFR mutations with brain metastases. Further randomized clinical trials are warranted.

Of the 16 pooled studies, 358 patients in 12 studies were administered EGFR-TKIs alone, while 70 patients in four studies were concurrently treated with WBRT and EGFR-TKIs. Subgroup analysis indicated that concurrent administration of WBRT and EGFR-TKIs might be more beneficial than administration of EGFR-TKIs alone in unselected patients, with an ORR of 66.2% versus 45.2% and a DCR of 94.4% versus 73.1%, respectively. Because no survival data were reported in the two studies of the concurrent treatment groups, we could not infer whether the enhanced ORR and DCR for the concurrent treatment groups suggested a survival advantage. Although blockade of EGFR signaling in vitro has been shown to sensitize cells to the effects of radiation, this effect has not been confirmed in clinical studies. EGFR-TKIs showed high rates of remission in EGFR mutant patients with brain metastases, and concurrent administration of WBRT and EGFR-TKIs among these patients is being disputed. Recent data by Iuchi et al indicated that the adequate effect of gefitinib could withhold radiation therapy safety to avoid neurocognitive deterioration in patients with EGFR mutations and brain metastases. The ability of EGFR-TKIs to replace WBRT as a first-line treatment is under investigation (NCT01724801) in a stage III randomized clinical trial aimed to investigate whether icotinib enhances PFS compared with WBRT in patients with EGFR mutations and brain metastases.

Finally, subgroup analysis based on different EGFR-TKI agents indicated that gefitinib resulted in improved survival compared with erlotinib, with a PFS of 8.9 months versus 5.9 months and OS of 14.1 months versus 9.7 months. The different outcomes of erlotinib and gefitinib treatment may be due to the following. First, because the frequency of EGFR mutations is higher in Asian than in Caucasian populations, EGFR-TKIs may have had better efficacy in Asian patients in the unselected group. In our data, clinical studies with gefitinib were mainly conducted in the Asian population, while those with erlotinib were not. Second, bias may be induced by small-sized and nonrandomized studies. Case reports have shown that erlotinib shows a benefit in gefitinib failure patients with brain metastases, and some investigations indicate that the rate of penetration of the brain barrier by erlotinib is higher than that for gefitinib. Thus, it is tempting to conclude that erlotinib is more efficacious than gefitinib. However, our pooled analysis does not support this conclusion. Further studies are needed to compare different EGFR-TKI agents in these patients.

The present pooled analysis has some limitations. First, the random-effects model used in part of the analysis may weaken the effect of a large sample with better quality and increase the effect of a small sample with worse quality. Second, because the review was limited to the published literature, and individual participant data are the gold standard for conducting meta-analyses, a potential impact of publication bias could not be ruled out. Third, the number of enrolled cases in some of the studies was relatively small because research focused on a specified patient population is rare. Fourth, heterogeneity might occur due to differences in the treatments that the patients in most of the unselected studies received before EGFR-TKI treatment. Finally, all of the studies were single-arm studies without randomization and blinding, and the comparability was poor. Thus, further studies, particularly prospective studies without randomization and blinding, are needed to provide sufficient data for in-depth evaluation. All of these limitations likely affected the final results.

**Conclusion**

In conclusion, our pooled analysis demonstrated that EGFR-TKIs are an effective treatment for NSCLC patients with brain metastases, particularly in the subgroup with activating EGFR mutations. Therefore, we emphasize that patients with NSCLC should be tested for EGFR mutations. The combination of EGFR-TKIs with WBRT might improve intracerebral ORR and DCR for unselected patients, but the effect of combined treatment in patients with activating EGFR mutations is unclear. Larger prospective randomized clinical trials are needed to provide sufficient data for in-depth evaluation. All of these limitations likely affected the final results.
warranted to confirm the efficacy of EGFR-TKIs alone in patients with activating EGFR mutations.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


